**Not financial advice**
ITRM under $1 whilst being in NASDAQ, will need to reclaim the $1 before february. This will shoot up toward end of year whilst penny stocks are hot. looking to fill that $1.09 gap fill soon. Small amount of volume will send this. 15% risk at lows of 0.50 and potential profits of 87%.
@IbzzB - Twitter
Contextual immersion trading strategy idea.
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States.
The demand for shares of the company looks higher than the supply.
This and other conditions can cause a rise in the share price in the next...
Well, doesn't this look familiar? ITRM tested is previous level of support AND resistance in a wide channel today. IDK what the sell-off was but I'm guessing the re-entry had something to do with speculation on the FDA data set to come out next month.
"At the end of May, Iterum provided an update on its New Drug Application with the U.S. Food and Drug...
I'm new to technical analysis, but this looks like a descending wedge pattern to me. Bullish, needs confirmation of the PDUFA date and can rocket. I listened to their CC this morning, ITRM is in communication and collaboration with FDA. They said as far as they know, the FDA approval can still be late July as planned. I'm bullish, I'd love to hear others thoughts.
Item Therapeutics, Inc
Bought 500 ITRM @$1.60. Target @$8.00 date Jan 10,2022
Buy limit 500 ITRM @$1.40. Target @$10.00 date May 2,2022
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing significantly
differentiated anti-infectives aimed at combating the global crisis of multi-drug resistant (MDR) pathogens.
Company...
